CAMBRIDGE, Mass. � January 6, 2005 � Therion Biologics today announced the establishment of a clinical advisory board (CAB) to assist in directing the Company�s product development strategies. Therion�s lead product candidate, PANVAC�-VF, is a therapeutic cancer vaccine that is currently in a Phase III clinical trial for the treatment of patients with pancreatic cancer. The clinical advisory board will support the ongoing clinical development of PANVAC�-VF in additional indications such as colorectal cancer, ovarian cancer, lung cancer and breast cancer.

�We are privileged to have the guidance of such a distinguished group of advisors who have directed late stage clinical trials in multiple different cancers,� stated Thomas J. Schuetz, M.D., Ph.D., Chief Medical Officer at Therion. �This Clinical Advisory Board is a valuable resource to Therion as our portfolio of promising novel cancer therapies advances toward commercialization.�

The Therion Clinical Advisory Board includes:

Al B. Benson III, M.D., F.A.C.P. � Dr. Benson is a Professor of Medicine in the Division of Hematology/Oncology at Northwestern University�s Feinberg School of Medicine in Chicago, Illinois. He is also the Associate Director for Clinical Investigations and Chair of the Clinical Protocol Scientific Review and Monitoring System for the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, at Northwestern University�s Feinberg School of Medicine. Dr. Benson�s research is primarily in the areas of gastrointestinal cancer clinical trials, biologic therapies, Phase I cancer clinical trials and cancer chemoprevention.

Jordan D. Berlin, M.D. � Dr. Berlin is Associate Professor of Medicine and Clinical Director of GI Oncology at Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee. In addition, he is a practicing physician at Nashville Veterans Affairs Medical Center (VAMC). Dr. Berlin sits on the editorial board of the International Journal of Gastrointestinal Cancer, is Editor-in-Chief of Colorectal Cancer Index and Reviews, and has written nearly 100 published pieces. Dr. Berlin earned his medical degree from the University of Illinois College of Medicine in Chicago, Illinois.

Matthew Kulke, M.D. � Dr. Kulke is Assistant Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute (DFCI). Dr. Kulke, who has led a number of clinical trials for patients with gastrointestinal malignancies and neuroendocrine tumors, is currently focusing on the identification of molecular targets and novel treatment strategies for patients with these diseases. Dr. Kulke is a graduate of Princeton University, and received an M.D. from the University of California, San Francisco School of Medicine in 1992.



Howard L. Kaufman, M.D., F.A.C.S. � Dr. Kaufman is Vice Chairman of Surgical Oncology, Department of Surgery and Associate Professor of Clinical Surgery (in Pathology) at Columbia University�s College of Physicians and Surgeons. His research interests are tumor vaccines, tumor immunology, mouse models of cancer, clinical vaccines for melanoma, colon cancer, prostate cancer, and Interleukin-2 (IL-2) for melanoma and renal cell carcinoma.

John L. Marshall, M.D. � Dr. Marshall is the Director of the Developmental Therapeutics program and Associate Professor of Oncology and Medicine at the Lombardi Comprehensive Cancer Center at Georgetown University. Dr. Marshall specializes in clinical trials for new cancer therapeutic agents and is widely published in his field. Dr. Marshall earned his M.D. from the University of Louisville�s School of Medicine and completed his specialty training in oncology at Georgetown University and a research fellowship at the Lombardi Comprehensive Cancer Center for the American Cancer Society.

John J. Nemunaitis, M.D. � Dr. Nemunaitis is Executive Medical Director of the Mary Crowley Medical Research Center and directs the JT Mallums Viral Gene Sequencing Laboratory. He specializes in medical oncology and hematology and has been involved with numerous presentations to FDA and FDA support committees for new product development advancement. He has authored over 190 papers in his area of molecular targeting for cancer therapy.

Daniel D. Von Hoff, M.D. � Dr. Von Hoff is one of the world�s most experienced and respected clinical oncologists and oncology drug developers, having conducted national clinical trials with more than 140 new anti-neoplastic and biologic agents. He has served as Director of the Arizona Cancer Center and Professor of Medicine at The University of Arizona Health Sciences Center, the President of the American Association for Cancer Research, and a Member of the Board of Scientific Advisors of the National Cancer Institute. Dr.Von Hoff has served on the FDA�s Oncologic Drugs Advisory Committee and the board of the American Society of Clinical Oncology.

About Therion Biologics Corporation
Therion Biologics Corporation develops therapeutic vaccines that aim to extend and improve the lives of cancer patients. The company has two lead product candidates: PANVAC�-VF, currently in a Phase III clinical trial for pancreatic cancer, and PROSTVAC�-VF, currently in a Phase II clinical trial for prostate cancer. The company is applying its technology to develop its vaccine pipeline, including treatments for breast cancer, lung cancer, and vaccines for the prevention of AIDS. For more information, please visit www.therion.com.

Therion Contact:
Titus Plattel
Sr. Director, Marketing
Therion Biologics
617.475.7312

Media:
Kari Lampka or Jennifer Gray
MacDougall BioCommunications, Inc.
508.647.0209
[email protected] or [email protected]